Physician profile
Shanka Nandi
NPI 1437326410
$4,985.26
in general payments reported to CMS, 2019-2025
28 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $368 · 2021: $302 · 2022: $984 · 2023: $968 · 2024: $1,016 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,651 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,650.66 |
| Education | $159.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,042.51 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $689.04 | 2021-2025 | |
| Vifor Pharma, INC. | $660.74 | 2019-2025 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $334.26 | 2021-2023 | Benlysta |
| Ardelyx, INC. | $329.41 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Amgen INC. | $241.05 | 2019-2025 | Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $204.47 | 2019-2024 | Jynarque |
| Akebia Therapeutics INC | $201.82 | 2019-2025 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $198.53 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $197.84 | 2023-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $162.27 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $124.87 | 2023-2025 | Filspari |
| Novo Nordisk INC | $71.10 | 2023-2025 | Ozempic, Rybelsus |
| Mallinckrodt Hospital Products INC. | $65.98 | 2021-2024 | Acthar |
| Mallinckrodt Enterprises LLC | $61.10 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $58.26 | 2025 | Purified Cortrophin Gel |
| Medtronic, INC. | $51.03 | 2025 | Symplicity G3 |
| Opko Pharmaceuticals, LLC | $44.48 | 2022 | |
| Novartis Pharmaceuticals Corporation | $42.07 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $30.30 | 2023 | Ultomiris |
| Genzyme Corporation | $28.43 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.10 | 2024 | Jardiance |
| Lilly USA, LLC | $24.83 | 2022 | |
| Fresenius USA Marketing, INC. | $23.54 | 2023 | Velphoro |
| Ultragenyx Pharmaceutical INC. | $22.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.74 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.08 | 2019 | |
| Boston Scientific Corporation | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanka Nandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.